stockrow
Friday 6 November 2026
Export SMMT’s income statement to Excel — free account
Summit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
- EPS
- +63.2%
- Free cash flow
- −112.8%
Quarter to June 2026, against a year earlier
15.97
1.78
+12.54%
Follow SMMT
Alert me
Summit Therapeutics PLC (SMMT) Revenue
Summit Therapeutics PLC's revenue for fiscal 2022 was $705.0K, down 61.0% from $1.8M in fiscal 2021. Over the past ten years it has ranged from $705.0K (fiscal 2022) to $57.1M (fiscal 2019) — the current reading is the lowest in ten years. Summit Therapeutics PLC ranks 325th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2022 | $705.0K | (61.03%) |
| FY2021 | $1.8M | 110.35% |
| FY2020 | $860.0K | 15.75% |
| FY2019 | $743.0K | (98.70%) |
| FY2019 | $57.1M | 255.15% |
| FY2018 | $16.1M | (51.43%) |
| FY2018 | $33.1M | 971.11% |
| FY2017 | $3.1M | 0.19% |
| FY2017 | $3.1M | 242.23% |
| FY2016 | $900.7K | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Dec 2022 | $0.00 | — |
| Sep 2022 | $220.0K | (6.38%) |
| Jun 2022 | $235.0K | (6.00%) |
| Mar 2022 | $250.0K | (0.40%) |
| 23 more quarters | Free account |
Against its own ten years
Low $705.0K
High $57.1M
Ten-year median
$2.4M
Current reading's percentile
10
Revenue against peers
| Company | Revenue |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $4.7B |
| BMRN BioMarin Pharmaceutical Inc. compare | $3.7B |
| HALO Halozyme Therapeutics, Inc. compare | $1.8B |
| TECH Bio-Techne Corp compare | $1.2B |
| ASND Ascendis Pharma A/S compare | $1.2B |
| BBIO BridgeBio Pharma, Inc. compare | $945.5M |
| KYMR Kymera Therapeutics, Inc. compare | $105.0M |
| SMMT Summit Therapeutics PLC | $705.0K |
| PCVX Vaxcyte, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on SMMT
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement